Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.57 |
| ▸ | AURKA | O14965 | 4/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18108703 | 0.94 | FLT3 (0.52) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18120908 | 0.91 | AURKA (0.63) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18120912 | 0.88 | FLT3 (0.55) | FLT3AURKANTRK1INSRIGF1R | |
| Trifluoroacetic Acid SCHEMBL18108601 | 0.86 | AURKA (0.59) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18108695 | 0.84 | AURKA (0.71) | FLT3AURKANTRK1INSRIGF1R | |
| Trifluoroacetic Acid SCHEMBL18108600 | 0.83 | FLT3 (0.50) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18120896 | 0.83 | FLT3 (0.60) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18108770 | 0.83 | AURKA (0.61) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18108549 | 0.83 | CDK7 (0.49) | FLT3AURKANTRK1INSRIGF1R | |
| SCHEMBL18108681 | 0.82 | AURKA (0.56) | FLT3AURKANTRK1INSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | TNIK, TNNI3K, TNK1 | FLT3 1518/4885AURKA 361/4885NTRK1 254/4885 |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNNI3K, TNK1 | FLT3 1550/4885AURKA 374/4885NTRK1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.